Vandana Dua Niyyar

Vandana Dua Niyyar

Auto-generated profile, based on publicly available information

Vandana Dua Niyyar

Division of Nephrology, Department of Medicine, Emory University, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
DKDinesh Khanna
Dinesh Khanna
John FitzGeraldJohn FitzGerald
John FitzGerald
PKPuja Khanna
Puja Khanna
SBSangmee Bae
Sangmee Bae
MSManjit K. Singh
Manjit K. Singh
RTRobert Terkeltaub
Robert Terkeltaub
Click on the article title to read more.

28 September 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
DKDinesh Khanna
Dinesh Khanna
PKPuja Khanna
Puja Khanna
John FitzGeraldJohn FitzGerald
John FitzGerald
MSManjit K. Singh
Manjit K. Singh
SBSangmee Bae
Sangmee Bae
RTRobert Terkeltaub
Robert Terkeltaub
Click on the article title to read more.

20 July 2017 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
GBGerald A. Beathard
Gerald A. Beathard
CLCharmaine E. Lok
Charmaine E. Lok
MGMarc H. Glickman
Marc H. Glickman
AAAhmed A. Al-Jaishi
Ahmed A. Al-Jaishi
DBDonna Bednarski
Donna Bednarski
THThomas S. Huber
Thomas S. Huber
This paper is part of the Clinical Trial Endpoints for Dialysis Vascular Access Project of the American Society of Nephrology Kidney Health Initiative. The purpose of this project is to promote research in vascular access by clarifying trial end points which would be best suited to inform decisions in those situations in which supportive clinical data are required. The focus of a portion of the project is directed toward arteriovenous access. There is a potential for interventional studies to be directed toward any of the events that may be associated with an arteriovenous access’ evolution throughout its life cycle, which has been divided into five distinct phases. Each one of these has the potential for relatively unique problems. The first three of these correspond to three distinct stages of arteriovenous access development, each one of which has been characterized by objective direct and/or indirect criteria. These are characterized as: stage 1—patent arteriovenous access, stage 2—physiologically mature arteriovenous access, and stage 3—clinically functional arteriovenous access. Once the requirements of a stage 3—clinically functional arteriovenous access have been met, the fourth phase of its life cycle begins. This is the phase of sustained clinical use from which the arteriovenous access may move back and forth between it and the fifth phase, dysfunction. From this phase of its life cycle, the arteriovenous access requires a maintenance procedure to preserve or restore sustained clinical use. Using these definitions, clinical trial end points appropriate to the various phases that characterize the evolution of the arteriovenous access life cycle have been identified. It is anticipated that by using these definitions and potential end points, clinical trials can be designed that more closely correlate with the goals of the intervention and provide appropriate supportive data for clinical, regulatory, and coverage decisions.

1 May 2018 in Kidney International
Verified
Journal Article
Closed access
VNVandana Dua Niyyar
Vandana Dua Niyyar
WOW. Charles O’neill
W. Charles O’neill

30 September 2009 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
VNVandana Dua Niyyar
Vandana Dua Niyyar
HWHaimanot Wasse
Haimanot Wasse

1 July 2013 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
VNVandana Dua Niyyar
Vandana Dua Niyyar
MCMicah R. Chan
Micah R. Chan
Summary: Despite recommendations by various national guidelines advocating arteriovenous fistulae as the access of choice in patients undergoing hemodialysis (HD), the use of central venous catheters (CVCs) remains widespread among both incident and prevalent HD patients. Unfortunately, long-term use of CVCs is fraught with complications, which are a major cause of morbidity and death in this patient population. Complications include a high rate of infections, as well as thrombus and sheath-related mechanical dysfunction. This review addresses prevention and management of noninfectious catheter-related dysfunction.